Initial Antiretroviral Therapy in an Integrase Inhibitor Era: Can We Do Better?

ABSTRACT: With the second-generation integrase inhibitors (dolutegravir and bictegravir) extending the attributes of earlier integrase inhibitors, three-drug regimens containing integrase inhibitors plus two nucleos(t)ide reverse transcriptase inhibitors are now widely recommended for first-line (initial) treatment of human immunodeficiency virus-1 infection. Led by dolutegravir plus lamivudine, two-drug therapy is emerging as a way to reduce antiretroviral therapy cost and adverse effects without compromising treatment options should virologic failure occur. Initial two-drug therapy has limitations, including the relative incompatibility with the coemerging concept of same-day antiretroviral therapy initiation.

SUBMITTER: Kelly SG 

PROVIDER: S-EPMC7178329 | biostudies-literature | 2019 Sep

REPOSITORIES: biostudies-literature